Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome

NCT02060409 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02060409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02060409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
January 31, 2012
Completion date
February 28, 2014
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome